Floatz logo

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)

Adult Acute Lymphocytic Leukemia

University of Washingtonprotein_peptidePhase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the Adult Acute Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
Shanxi Bethune Hospital
Phase 4A
DEXAMETHASONE
Shanxi Bethune Hospital
Phase 4BBB
Cytosin-Arabinosid
PETHEMA Foundation
Phase 4BBB
VINDESINE
Shanxi Bethune Hospital
Phase 4BBB
ASPARAGINASE
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BBB

View all 15 →

Same molecule, other indications

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:

Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →
L1 Childhood Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →